May et al. investigated the effect of DNA-damaging by phosphor-H2AX staining, apoptosis agents (including p53 and Musashi-1 (MSI-1)), and proliferation agents (including proliferating cell nuclear antigen (PCNA)) on the eradication of DCLK1-expressed cells in APCmin/+ mice, and they suggested DCLK1 as a potential therapeutic target in CRC and intestinal cancer treatments [47]. This evidence concerns the gene DCLK1 and colorectal carcinoma.